In the current study, we further examined the impact of treatment with adefovir dipivoxil on the frequency of CD95+ B cells and IgD+ B cells in patients with chronic viral hepatitis and found that treatment with adefovir dipivoxil for 12 weeks not only significantly decreased the concentrations of serum ALT, serum AST, HBV virus, HBsAg, and HBeAg, but also dramatically increased the concentrations of HBsAb and HBeAb and the frequency of CD95+ B cells and IgD+ B cells in the drug-responding HBV patients. The gene discussed is GPT; the disease is animal viral hepatitis.